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Abstract The management of medication overuse head-
ache (MOH) is based essentially on the withdrawal of the
overused drug(s). Drug withdrawal is performed according
to widely differing protocols, both within and across coun-
tries; therefore, therapeutic recommendations for the acute
phase of detoxification vary considerably among studies.
Basically, the aims of MOH management are: (a) to with-
draw the overused drug(s); (b) to alleviate withdrawal
symptoms by means of a bridge therapy, which includes
pharmacological and non-pharmacological support,
designed to help the patient to tolerate the withdrawal pro-
cess; (c) to prevent relapse. Today, there is extensive debate
over the best strategies for achieving these goals and the
different aspects of this debate are discussed in this review.
The authors searched for the best available evidence relating
to the following questions: should medication withdrawal be
abrupt or gradual? Should patients receive replacement
therapy? What are the most effective therapeutic pro-
grammes for controlling withdrawal symptoms? Should
replacement therapy be administered routinely or as rescue
therapy? Should preventive treatment be started before,
during or after withdrawal? What are the most effective
preventive treatments? Should patients be managed through
inpatient or outpatient withdrawal programmes? What is the
best approach to adopt in preventing relapses? Treatment of
MOH is a difficult challenge, but may be very rewarding.
Although there is still a lack of high-quality studies pro-
viding evidence-based answers to the many specific ques-
tions it raises, neurologists need to know that the
combination of education with a rational use of selected
therapeutic strategies may be beneficial to people with
chronic headache and help to relieve their suffering.
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Background
Over the past 15 years, clinical experience and scientific
studies on medication overuse headache (MOH) have
accumulated, providing the basis for revisions of the Inter-
national Classification of Headache Disorders (ICHD-II)
diagnostic criteria [1, 2] and for the proposal (the practical
details of which remain to be worked out) of a pragmatic
clinical distinction between simple and complicated MOH
(Table 1) [3, 4]. The ‘‘New appendix criteria for a broader
concept of chronic migraine’’ recently published by the
International Headache Society (IHS) [2] no longer require
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headache resolution or a return to the previous headache
pattern after drug discontinuation, to confirm the diagnosis.
These simplified diagnostic criteria will help physicians to
recognise MOH, thus removing the diagnostic barriers to
proper care of affected patients. In this scenario, there is an
increasing need for evidence-based and cost-effective drug
withdrawal strategies.
Drug withdrawal is the treatment of choice for MOH
[5–7]. Zeeberg et al. recently reported that mere discon-
tinuation of regular drug intake had, after 2 months,
reduced the mean headache frequency by 51% in
migraine, 18% in tension-type headache (TTH) and 33%
in patients with a combination of migraine and TTH [8].
They also found that MOH patients who had previously
failed to respond to preventive treatment became respon-
sive to medical prophylaxis after withdrawal of the acute
headache drugs they had been overusing [9]. A survey of
22 studies dealing with the therapy of drug-induced
headache revealed that most centres used drug withdrawal
as the first-choice therapy [5]. Drug withdrawal, however,
is performed very differently within and across countries
and therapeutic recommendations for the acute phase of
detoxification thus vary considerably among studies.
Moreover, the IHS only recently published its guidelines
for controlled trials of prophylactic treatment in chronic
migraine, including MOH [10]. Currently, there is a lack
of prospective, controlled trials in this field, and treatment
effectiveness is basically inferred from the results of open-
label trials, retrospective case reviews, anecdotal obser-
vations, clinical experience and generalisations from the
literature on primary headaches. As a result, no formal
evidence-based recommendations for optimal therapy can
be made and, in general, published guidelines reflect the
personal experience of the authors and/or the best avail-
able evidence [11–14].
Basically, the aims of MOH management are: (a) to
withdraw the overused drug; (b) to alleviate withdrawal
symptoms by means of a bridge therapy, including phar-
macological and non-pharmacological support, designed to
help the patient to tolerate the withdrawal process; and (c)
to prevent relapse [13, 15].
Today, there is extensive debate on the best strategies
for achieving these goals and the different aspects of this
debate are discussed in this review (Table 2).
Should medication withdrawal be abrupt or gradual?
No study has compared abrupt withdrawal with tapered
withdrawal in prospective randomised trials; therefore, no
formal evidence-based recommendation can be made.
However, the majority of headache specialists consider
drug withdrawal to be more effective if done abruptly
[12–14, 16]. Abrupt withdrawal is possibly associated with
less protracted suffering for the patient and faster resolu-
tion of the drug-centred pain-coping behaviour.
This is likely to apply particularly in overuse of triptans,
ergots, paracetamol, aspirin and NSAIDs, for which out-
patient withdrawal programmes can be appropriate. Con-
versely, due to the possibility of severe withdrawal
symptoms, patients overusing opioids, barbiturates or
benzodiazepines should have their medication withdrawn
gradually (i.e. reduced by 10–20% every week or two,
depending on the overused drug, the dose and the duration
of intake), preferably in the context of an inpatient pro-
gramme (clinical experience-based recommendation).
Should patients receive replacement therapy?
What are the most effective therapeutic programmes
for controlling withdrawal symptoms?
Should replacement therapy be administered routinely
or only as rescue therapy?
Symptomatic drug withdrawal leads to worsening of head-
ache and the onset of drug withdrawal symptoms such as
Table 1 Proposed criteria for simple or complex medication overuse headache (see references [3, 4])
Simple MOH Complex MOH
Short duration of MOH (3 months–1 year) Long duration of MOH ([1 year)
Relatively modest doses of drugsa Daily opioids or combination medication with more than
one prescription drug
Minimal psychiatric contributionb
(one or two axis I clinical syndromes)
Multiple psychiatric comorbidities including personality disorders
No history of relapse after withdrawal History of relapse following withdrawal
a Up to two triptans and three analgesics per day
b Psychological issues contributing to the perpetuation of MOH include: (a) the belief that drug(s) is(are) the only solution, (b) anticipatory fear
of pain (cephalalgiophobia), (c) difficulty tolerating discomfort, (d) sedation seeking, (e) outside pressure, need to function, (f) axis I, clinical
syndrome, (g) axis II personality disorders
408 J Headache Pain (2009) 10:407–417
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nausea, vomiting, arterial hypotension, tachycardia, sleep
disturbances, restlessness, anxiety and nervousness [5, 6].
Seizures and hallucinations have only rarely been observed,
even in patients overusing butalbital-containing agents.
Drug withdrawal symptoms typically last 2–10 days (aver-
age 3.5 days), but can persist for up to 4 weeks [7, 14].
Withdrawal symptoms are usually relieved by further intake
of the overused medication, but this could lead to perpetu-
ation of the overuse.
Withdrawal symptoms vary greatly depending on the
overused medication. The duration of the withdrawal
headache is shorter in patients overusing triptans (4.1 days)
than in those overusing ergots (6.7 days) or NSAIDs
(9.5 days) [17]. Withdrawal from triptans is generally
achieved in a short period of time (approximately 80% of
patients are headache-free 4 days after starting the therapy)
and without serious withdrawal symptoms [17, 18].
Many different replacement strategies for treating
medication withdrawal symptoms in MOH have been
proposed and found to be effective, almost exclusively in
uncontrolled, unblinded studies that employed a variety of
outcome measures [12, 19]. The proposed treatments
include different drug classes (used alone or in combina-
tion), such as antiemetics, analgesics, triptans, sedatives,
narcoleptics, central muscle relaxants and corticosteroids
(the drugs suggested include intravenous dihydroergota-
mine, lidocaine, intravenous valproic acid, tramadol,
clonidine, phenobarbital and amitriptyline), and other
Table 2 Clinical management of MOH: questions and answers
Should medication withdrawal be abrupt or
gradual?
No formal evidence-based recommendation can be made.
The majority of headache specialists consider drug withdrawal more effective if done
immediately. In general, triptans, ergots, paracetamol, aspirin and NSAIDs should be
stopped abruptly.
Should patients receive replacement therapy? Evidence from available controlled trials suggest that non-complicated MOH patients may
achieve successful drug withdrawal through the simple imparting of advice to withdraw
symptomatic medications and the use of rescue medications with limits on intake.
What are the most effective therapeutic
programmes for controlling withdrawal
symptoms?
Patients overusing drugs containing opioids, barbiturates or tranquillisers usually require a
replacement therapy (clinical experience-based recommendation).
Should replacement therapy be administered
routinely or as rescue therapy?
Although this is not yet supported by scientific evidence, patients overusing analgesics,
ergots, combination drugs or combinations of acute medications (especially those using
multiple daily doses), who experience intolerable withdrawal symptoms or present medical
and psychiatric illnesses that could complicate their withdrawal programme, should be
considered for regular replacement therapy, whether symptoms are present or not
(clinical experience-based recommendation).
No evidence-based recommendation can be made on the most effective replacement therapy
in these patients.
Should preventive treatment be started before,
during or after withdrawal?
No evidence-based recommendation can be made on the use of preventive treatment
(who, when and what) for the clinical management of MOH.
In non-complicated MOH patients, the decision on whether or not to start a preventive
treatment may be postponed until a follow-up visit performed 2–3 months after the start of
the withdrawal treatment. Complicated MOH patients, especially those who already had a
high headache frequency before development of medication overuse and who had tried
more than one preventive treatment in the past, probably need early prophylaxis
(clinical experience-based recommendation).
What are the most effective preventive
treatments?
There are no evidence-based indications supporting the use of specific preventive drugs in
MOH (valproic acid as well as topiramate have been shown to have beneficial effects in the
prophylactic treatment of chronic migraine, complicated by excessive analgesic intake in
open-label and double-blind trials).
Should patients be managed through inpatient
or outpatient withdrawal programmes?
No evidence-based recommendation can be made. In non-complicated MOH patients,
effective drug withdrawal may be obtained in an outpatient setting. MOH patients
overusing opioids, barbiturates or benzodiazepines, or presenting psychological problems
or medical illnesses liable to complicate withdrawal programmes undertaken on an
outpatient basis, are candidates for hospitalisation, as are those who have previously failed
as outpatients or who lack the motivation needed to undertake an outpatient withdrawal
programme (clinical experience-based recommendation).
What is the best approach to adopt to prevent
the relapse?
The fact that a large proportion of MOH patients are at risk of relapse after withdrawal
provides an indication of the lack of effective strategies for preventing this outcome.
The most practical strategy in MOH is to prevent medication overuse through education and
early and appropriate headache prophylaxis in patients who present a high headache
frequency (author’s personal view).
J Headache Pain (2009) 10:407–417 409
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preventive medications, oxygen, electrical stimulation and
fluid replacement [12, 19, 20].
These treatments have been tested both in inpatient and
in outpatient regimens. However, the fact that they are
often used in combination with preventive and educational
interventions makes it difficult to understand the efficiency
of the treatments per se, as well as their reproducibility in
other settings. Bridge therapies are regularly prescribed,
usually administered for short periods, in other cases
administered on demand (rescue treatment) and in some
cases with limits on intake.
Because all drugs used for the acute treatment of
headache can cause MOH, corticosteroids are an attractive
option for the treatment of withdrawal headache. In a large
open-label trial investigating patients with chronic daily
headache and medication overuse, oral prednisone (60 mg
as a starting dose, then tapering down by 20 mg every
second day), as part of an outpatient regimen, effectively
reduced withdrawal symptoms, including rebound head-
ache [21]. Conversely, a recent Norwegian placebo-con-
trolled study showed that prednisolone (60 mg as a starting
dose, then tapering down by 20 mg every second day),
given as part of an inpatient regimen for 6 days, was
ineffective in treating withdrawal headache [22]. This latter
study included patients with both TTH and migraine. In a
very recent study, intended as a proof-of-concept uncon-
trolled study, prednisone 100 mg, given once a day for the
first 5 days of withdrawal as part of an inpatient strategy,
was effective in reducing medication withdrawal headache
in 20 MOH patients with migraine as a primary headache
[23]. Thus, in the only high-quality study available, ste-
roids administered in the acute phase of drug withdrawal
seem ineffective. High-quality randomised placebo-con-
trolled trials using higher dosages and taking into account
the clinical heterogeneity of MOH are needed.
Three recent prospective randomised controlled trials
(two open-label and one double-blind) compared the effi-
cacy of different therapeutic regimens following abrupt
withdrawal of the overused medication [22, 24, 25].
Rossi et al. [24] randomly allocated 120 simple MOH
patients (no previous detoxification treatments, no coexis-
tent, significant and complicating medical illnesses, no
current psychiatric comorbidity, no overuse of agents con-
taining opioids, benzodiazepines or barbiturates, migraine
as primary headache) to one of three groups, each of 40
subjects: Group A received only strong advice to withdraw
overused medication(s); Group B underwent a standard
outpatient detoxification programme based on advice to
withdraw, abruptly, overused medication(s) ? oral predni-
sone for the first 8 days? personalised preventive treatment
starting on day 1; Group C underwent a standard inpatient
drug withdrawal programme based on the abrupt discon-
tinuation of overused medication(s) ? oral prednisone for
the first 8 days? personalised preventive treatment starting
on day 1 ? parenteral fluid replacement and administra-
tion of antiemetics ? close observation and support for
8 days.
Krymchantowski and Moreira [25] randomised 150
MOH outpatients (diagnosed according to the Silberstein–
Lipton criteria), who were moderate overusers of acute
drugs (excluding opioids, barbiturates and tranquillisers),
to a tapering course of prednisolone, regular naratriptan or
no regular medication for 6 days, in addition to advice and
rescue medication (indomethacin or chlorpromazine). All
the patients were started on prophylaxis on day 7 (atenolol,
nortriptyline or flunarizine).
Boe et al. [22] evaluated 100 MOH inpatients, who had
no psychiatric or physical comorbidity and were not
overusing opioids or barbiturates; these patients received
prednisolone or placebo and pre-withdrawal advice, and
were allowed to take antiemetics, antihistaminic drugs and
antipsychotics, if necessary.
After a follow-up period ranging from 8 days to
2 months, none of these three studies found any between-
group differences in:
• the percentage of patients achieving successful with-
drawal [24, 25];
• headache frequency [24, 25];
• headache intensity [25];
• calculated mean headache [22].
It is worth noting, however, that in the study by
Krymchantowski and Moreira [25], the patients not
receiving bridge therapy experienced more symptoms and
required more rescue medication.
The findings of available randomised controlled trials
indicate that in patients with simple MOH, especially in
those with migraine as the primary headache, effective
drug withdrawal can be achieved through the imparting of
advice alone, although the use of medication (on a routine
or rescue basis) can be effective as well. This may have
important economic implications, if we consider the costs,
per detoxified patient, of the different strategies emerging
in the study by Rossi et al.: the simple imparting of advice,
€40; the outpatient programme (including replacement
therapy), €116; and the inpatient programme, €2,876
(Rossi et al., unpublished data).
In summary:
(a) Simple MOH patients may achieve successful drug
withdrawal through the simple imparting of advice to
withdraw symptomatic medications and the use of
rescue medications with limits on intake (evidence
from available randomised controlled trials). Effec-
tive education of MOH sufferers is crucial to proper
management, and information should be imparted to
410 J Headache Pain (2009) 10:407–417
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all patients in accordance with the principles summa-
rised in Table 3. Rescue treatment should be tailored
to the patient on the basis of his or her medical
history, headache characteristics and previous thera-
peutic experiences, and adherence to the rule that
patients should not be prescribed, as a rescue drug, the
drug that they had been overusing.
(b) Patients overusing drugs containing opioids, barbi-
turates or tranquillisers require a replacement ther-
apy regimen, which may include the short-term use
of long-acting opioids, phenobarbital, clonidine
(depending on the overused drug), hydration and,
if necessary, antiemetics [12–14, 20]. No formal
recommendation on support therapy in these patients
can be made and placebo-controlled studies are
needed.
(c) Although this is not yet supported by scientific
evidence, patients overusing analgesics, ergots, com-
bination drugs or combinations of acute medications
(especially those using multiple daily doses), who
experience intolerable withdrawal symptoms or pres-
ent medical and psychiatric illnesses that could
complicate their withdrawal programme, should be
considered for regular replacement therapy, whether
symptoms are present or not. No formal recommen-
dation can be made on the most effective replacement
therapy in these patients. A single course of naproxen
or tapered steroids, with or without antiemetics, and
adequate hydration are the therapeutic measures most
frequently included in guidelines suggested by experts
[12–15, 19, 20]. Again, well-designed, double-blind
controlled trials are needed.
Should preventive treatment be started before,
during or after withdrawal?
High-quality studies investigating the usefulness of pre-
ventive treatment in the acute phase of drug withdrawal are
lacking. In the study by Rossi et al. [24], personalised
preventive therapy started on day 1 did not improve the
outcome of withdrawal therapy. In the Danish study of 175
MOH patients [8], preventive therapy was initiated after a
2-month withdrawal period and actually found to be
necessary in only 47% of the patients; in the other 53%,
headache frequency was markedly reduced simply by dis-
continuation of the overused medication (in this study, 36%
of the patients failed to remain drug-free after receiving
advice to withdraw the overused medication). Hagen et al.
[26], in a recently published prospective, multicentre study,
investigated the effect of early introduction of prophylactic
treatment in three groups of MOH patients. In the pro-
phylaxis group (n = 17), patients received personalised
preventive medication from day 1; the abrupt withdrawal
group (n = 20 patients) received advice to withdraw
abruptly the overused medication plus rescue therapy,
whilst the controls (n = 19) received no preventive medi-
cation and no explicit advice to withdraw the overused
medication. The primary outcome measure, i.e. the change
in headache days/month, was not found to differ signifi-
cantly among groups. The prophylaxis group recorded the
most consistent reduction in headache days/month at
months 3, 5 and 12, though the mean headache frequency
continued to be greater than 15 days/month in all the
groups. All three groups recorded significant reductions in
days with use of acute medication per month, when com-
pared with baseline, the change being greatest in the abrupt
withdrawal group versus the controls (-19.1 vs. -6.9 at
month 3, p = 0.002). The prophylaxis group, compared
with the withdrawal group, showed significantly more
pronounced reductions in total headache index at months 3
and 12, and in sick leave days/month at months 5 and 12.
During the follow-up, the proportion of responders, defined
as patients no longer overusing symptomatic medications
or with a greater than 50% reduction in headache days,
tended to be higher in the prophylaxis group. The authors
concluded that early introduction of preventive treatment,
in the absence of previous detoxification reduced total
headache suffering more persistently than abrupt with-
drawal, challenging the notion that drug withdrawal is
necessary to obtain reduced headache frequency and a
response to prophylactic treatment. Unfortunately, the
results of this study are weakened by several methodo-
logical flaws. First, all the patients received written infor-
mation on MOH and the therapeutic importance of
withdrawing the acute medication, and this may have
influenced the behaviour both of the prophylaxis group
members and the controls (indeed, 26% of the controls
Table 3 Pillars of the
educational approach to MOH
sufferers
Explanation of the role of medication overuse in making headache chronic and in reducing the effectiveness
of preventive and behavioural treatments
Explanation in detail of the phenomenon and symptoms of withdrawal headache
Emphasis on the beneficial long-term effects, on headache natural history, of reducing symptomatic
medication intake (including reduction of the disease-reinforcing properties of short-term pain relief)
Discouragement of anticipatory use of medication
Emphasis on the need for a detoxification programme prior to other therapeutic options
J Headache Pain (2009) 10:407–417 411
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spontaneously reduced their drug intake considerably).
Second, since 72% of the patients in the withdrawal group
received a preventive therapy at month 3, the differences
observed from month 5 to 12 may be only poorly attrib-
utable to the different initial therapeutic strategies. Fur-
thermore, in view of the heterogeneity of MOH, the
number of patients included in the study, which was below
the power calculation, was too low. In addition, almost
30% of the MOH patients included in this study overused
opioids (vs. 42% of the controls); opioid overusers are
usually excluded by studies of this kind, investigating the
effectiveness of different treatment strategies in MOH,
because they can present withdrawal symptoms liable to
complicate the withdrawal process, and this aspect may
have contributed to determining the low success rate
observed in this study. Finally, with regard to the differ-
ences in the outcome measures observed at month 3, only
the reduction in headache index showed a statistical dif-
ference among groups in favour of the prophylaxis group;
for all the other parameters, only non-significant differ-
ences were observed. For all the above reasons, the
authors’ conclusions appear speculative. There is still a
need for further prospective, large-scale randomised trials
to establish the usefulness of early preventive treatment for
MOH.
In summary:
(a) In simple MOH patients, the decision on whether or
not to start a preventive treatment may be postponed
until a follow-up visit performed 2–3 months after the
start of the withdrawal treatment (clinical experience-
based recommendation). This approach may help
patients to feel more in control of their headache, and
it also fits better with what is known about the natural
history of the disease.
(b) An alternative approach is to start preventive and
withdrawal treatments simultaneously, or to start
preventive therapy during the washout period, making
it clear to the patient that the treatment may not
become fully effective until MOH has been elimi-
nated. This approach has two potential advantages:
first, it may help to reduce reliance on symptomatic
medications, and, second, the prophylactic treatment
may improve the withdrawal symptoms and headache
frequency.
Complicated MOH patients, especially those who
already had a high headache frequency before medication
overuse developed and who had tried more than one pre-
ventive treatment in the past, probably need early pro-
phylaxis. But, currently no formal evidence-based
recommendation can be made on the use of preventive
treatment (who, when and what) for the clinical manage-
ment of MOH.
What are the most effective preventive treatments?
In the absence of evidence-based indications, the choice of
preventive agent in MOH patients should be based on the
primary headache type (migraine or TTH), the drug side-
effect profile, the presence of any comorbid and coexistent
conditions, and the patient’s preferences and previous
therapeutic experiences [15].
In clinical practice, a monotherapy approach is prefer-
able, selecting from the possible first-line treatments: beta-
blockers, tricyclic antidepressants, calcium antagonists,
tizanidine or anticonvulsants. It seems reasonable to start
with low dosages, to reduce the risk of adverse events, and
then to increase the dose progressively until a therapeutic
effect or adverse events appear [12–14]. Only when such a
first-line monotherapy approach fails does it become
advisable to look for an alternative second- or third-line
treatment.
In open-label trials, both valproic acid and topiramate
have shown beneficial effects in the prophylactic treatment
of chronic daily headache complicated by excess analgesic
intake [27, 28]. More recently, a double-blind trial tested
the efficacy and safety of topiramate in patients with a
diagnosis of chronic migraine and MOH [29]. A total of 32
patients in the intent-to-treat population received topira-
mate and 27 patients received placebo for a period of
16 weeks (78% of these subjects met criteria for MOH).
Topiramate was titrated (25 mg weekly) to a target dose of
100 mg/day, allowing dosing flexibility from 50 to
200 mg/day, according to patient need. Topiramate pro-
duced a significant reduction in the mean number of
migraine days/month compared with placebo (-3.5 ± 6.3
vs. -0.2 ± 4.7, p \ 0.05). There emerged no significant
between-group differences in health-related quality of life.
The MIDAS questionnaires showed improvements in the
topiramate treatment group (p = 0.042 vs. placebo).
Treatment-emergent adverse events were reported by 75%
of the topiramate-treated patients (vs. 37% in the placebo
group). This randomised, double-blind, placebo-controlled
trial demonstrated that topiramate is effective, although
associated with a higher incidence of side effects when
used for the preventive treatment of chronic migraine, even
in the presence of MOH. However, the reported improve-
ment in terms of headache frequency appears poor and not
sufficient to constitute a reversion of the headache to its
previous episodic form.
There is thus a need for further well-designed, double-
blind, controlled trials investigating the effectiveness of
other preventive treatments, and prolonged, longer follow-
up periods.
Single injections of the greater occipital nerve with
anaesthetics or corticosteroids have been reported as
helpful in providing temporary relief from headache even
412 J Headache Pain (2009) 10:407–417
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in MOH patients, but further controlled studies are needed
to confirm these findings [30].
Should patients be managed in inpatient or outpatient
withdrawal programmes?
Rossi et al. [24], in their study of 120 patients with migraine
plus MOH, low medical needs and no previous detoxifica-
tion therapy, found simple advice to be as effective as
structured inpatient and outpatient detoxification pro-
grammes in achieving withdrawal from the overused med-
ication (approximately 75% of patients in all groups). In
addition, the level of adherence to treatment was compa-
rable with all three strategies (almost 90% of the initial
sample completed the study). These results are in line with
those of a previous German study, which suggested that
outpatient and inpatient programmes could be equally
effective [31]. Sick leave of 1 or 2 weeks may be needed
when patients are detoxified in an outpatient setting.
The inpatient therapeutic setting offers at least three
indisputable advantages. Namely, it allows: (1) close
monitoring of the patient’s medication intake and clinical
conditions, (2) prompt and adequate treatment of with-
drawal headache and associated symptoms; (3) the
administration of drugs that need continuous medical
monitoring (e.g. lidocaine, intravenous ergot derivatives).
As discussed in the previous paragraphs, different sup-
portive medication regimens have been proposed.
Headache experts and academic societies have published
recommendations that offer criteria for deciding between
in- and outpatient approaches (Table 4). It is generally
agreed that MOH patients overusing opioids, barbiturates
or benzodiazepines, or presenting psychological problems
or medical comorbidities, liable to complicate withdrawal
programmes undertaken on an outpatient basis, are candi-
dates for hospitalisation, as are those who have previously
failed as outpatients or who lack the motivation needed to
undertake an outpatient withdrawal programme.
These recommendations are not evidence based and
reflect, essentially, the authors’ experience and beliefs, as
well as basic principles of good clinical practice. Further-
more, the indications are not sufficiently specific. For
example, psychiatric comorbidity and socio-environmental
problems need better categorical and dimensional defini-
tion. Finally, these recommendations are the result of
experience accumulated in headache clinics. Thus, the
reproducibility in other settings (e.g. primary care) of the
protocols they suggest remains uncertain. Data from liter-
ature indicate that the strategy chosen (outpatient vs.
inpatient) is not a significant predictor of the long-term
success of withdrawal therapy [31, 32].
In summary, effective drug withdrawal may be obtained
simply in an outpatient setting, at least in MOH patients
presenting low medical needs and no previous experience
of detoxification therapy. Future controlled studies are
needed to establish whether outpatient programmes may be
considered as the first step in a step-care approach to MOH
Table 4 Published recommendations for outpatient and inpatient withdrawal from headache medication
Inpatient Outpatient




Previous failure as outpatient
Psychiatric comorbidity
Physical comorbidity
Fear of drug interactions
Motivated patients
Mild-moderate overuse
German Migraine and Headache
Society (1999)
Obermann and Katzarava [14]
Drugs (codeine, barbiturates, tranquillisers)
Depression
Previous medication withdrawal failure
Drugs (monosubstances, analgesic mixture not
containing barbiturates or codeine)
Highly motivated patients
Possibility of daily follow-up visits
Overall good compliance
British Association for the Study
of Headache (2007)
Drugs (overuse of high doses of opioids/
barbiturates/benzodiazepines)
Presence of psychiatric/behavioural disturbances
(in these cases the authors recommend referral to
specialist units or pain management clinics
offering neurological and psychiatric services)
No specific indication (the authors state that
admission to a hospital is rarely
necessary)
J Headache Pain (2009) 10:407–417 413
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management, in which patients progress through a
sequence of treatments (determined by a combination of
perceived effectiveness, safety and cost) until they find an
effective one, or as just one of the therapeutic options in a
stratified-care approach, in which patients, on the basis of
the extent of their medical needs, are assigned to different
treatments.
What is the best approach to adopt in preventing
relapses?
As stated by Obermann and Katsarava [14], the long-term
management of MOH is definitely more challenging than
acute drug withdrawal. Several studies have investigated
the long-term outcome of MOH following detoxification
and carefully evaluated possible relapse predictors.
MOH following successful drug withdrawal has a vari-
able, but mainly good, prognosis [5]. Success is usually
strictly defined as no headache at all or an improvement
(in terms of headache days/month) of more than 50%. In a
review of 17 studies (1,101 patients), the mean success rate
of withdrawal therapy, within a time window of 1–6 months,
was found to be 72.4% [5]. Three further studies considered
a longer observation period (9–35 months) [31–33] and
recorded success rates of 60, 70 and 73%, respectively.
Longer-term follow-up studies (4–6 years) found relapse
rates of between 40 and 60% [34–40]. These studies are
largely heterogeneous with regard to the definition of MOH,
populations under study, types of medication overused,
types of original primary headache, therapeutic approaches
and many other variables. Furthermore, most of them were
designed retrospectively.
Recent prospective studies that included patients with
triptan-induced MOH reported relapse rates after successful
drug detoxification therapy of 38% in the first year and
around 42% at 4 years [38, 41]. Patients with TTH had
higher relapse rates than migraine patients (77 vs. 23%,
respectively), and analgesic overusers had higher relapse
rates than ergot and triptan overusers (58 vs. 18 and 22%)
[41]. In a recent study, from Serbia, of patients not overusing
triptans, 39.6% of 240 patients had relapsed at the 1-year
follow-up [32]. The frequency of the primary headache
disorder, ergotamine overuse and pre-treatment disability as
measured by MIDAS were all found to be predictors of
relapse (the reported OR values and CIs actually raise some
question marks over the statistical interpretation of the
results). These, and older studies investigating rates and
predictors of relapse in MOH, were conducted on non-
selected populations of headache patients [5, 31, 40]. In a
recent publication, Rossi et al. [42] evaluated the rates and
predictors of relapse after successful drug withdrawal in a
previously studied population of simple MOH patients with
migraine as primary headache. The patients were followed
up prospectively for 1 year: relapsers were defined as
patients fulfilling, at follow-up, the new ICHD-II appendix
criteria for MOH. At the 1-year follow-up, the relapse rate
was found to be 20.5%, which is consistent with that
reported in the subgroup of patients with MOH plus
migraine studied by Katsarava et al. [41]. A binary logistic
regression analysis was performed and three variables
emerged as significant predictors of relapse: years with more
than eight migraine days per month (OR = 1.57, p = 0.01),
higher frequency of migraine attacks after drug withdrawal
(OR = 1.48, p = 0.04), and a greater number of previous
preventive treatments (OR = 1.54, p = 0.01). This study
suggests that in patients with migraine plus MOH and low
medical needs, the occurrence of relapse seems to depend on
a greater severity of baseline migraine. In the study by
Hagen et al. [26], the reduction in monthly headache days
was more pronounced in the individuals who had tried only
one or no preventive medications before inclusion than in
those who had tried two or more (6.1 vs. 1.3 days,
p = 0.02).
In short, the main findings of the investigations
addressing the long-term prognosis of MOH may be sum-
marised as follows:
• the literature data are heterogeneous due to the use of
different patient populations;
• relapse after withdrawal therapy is an important
concern even in patients with simple MOH;
• TTH patients are more likely to relapse than those with
migraine, probably due to the lack of effective TTH
prophylactics;
• the majority of patients who relapse do so in the first
year after withdrawal (many patients relapse within the
first 6 months);
• the withdrawal therapy strategy [31, 33], the use of
preventive treatment, the duration of migraine and the
duration of drug overuse, as well as socio-demographic
variables, have no impact on the outcome [31, 32, 39,
41], whereas discrepancies have emerged with regard to
the influence, on MOH prognosis, of the type of drug
overused;
• the role of additional factors, such as psychological and
social ones, on MOH prognosis has not been adequately
investigated;
• in MOH that has evolved from migraine as the primary
headache, relapse seems to depend on a greater severity
of migraine at baseline.
The fact that a large proportion of MOH patients are at
risk of relapse after withdrawal provides an indication of
the lack of effective strategies for preventing this outcome.
Even though many authors are in favour of starting first-
line preventive treatments as soon as possible [13, 14],
414 J Headache Pain (2009) 10:407–417
123
these treatments have no influence on the prognosis. It is
generally agreed that behavioural and psychological factors
could potentially influence the induction, maintenance and
outcome of MOH [3, 4, 6, 7, 43]. Consequently, many
authors consider the following to be essential aspects of
long-term management of MOH (clinical experience-based
recommendation):
• patient education (e.g. suggestions on how to improve
self-management of attacks, information on maximal
monthly dosages of symptomatic drugs, on what to
expect from preventive treatments, etc.);
• continuous support in the first year after withdrawal
(frequent follow-up visits, also involving, if necessary,
patients’family);
• continuous monitoring by means of a headache diary,
and behavioural therapies aiming to correct aberrant
pain-coping strategies and psychological factors con-
tributing to MOH [4, 13–15, 44, 45].
Currently, data on the effectiveness of these measures are
limited. In a quasi-randomised controlled trial (n = 61) the
addition of biofeedback-assisted relaxation therapy to pre-
ventive medication did not increase the success rate at
3 years and, though the patients in the combined group were
less likely to relapse, this finding did not reach statistical
significance when subjected to an intention-to-treat analysis
[46]. Recently, in a very limited number of MOH patients
(n = 27) having migraine as primary headache, it was shown
at the 12-month follow-up that the decrease in headache
frequency and medication intake was greater, and the relapse
rate lower, in patients receiving psychoanalysis-based psy-
chotherapy in addition to prophylactic treatment than in
those receiving only pharmacotherapy [47]. Of course, these
findings need to be confirmed in further randomised con-
trolled studies enrolling a larger number of patients.
All these data highlight the urgent need for future
research into effective relapse prevention strategies and
strengthen the notion that the most practical strategy in
MOH is to prevent medication overuse through education
and early, appropriate headache prophylaxis in patients
with high headache frequency.
Conclusions
Management of medication overuse can be very rewarding,
but it is, in general, difficult. This is due to a number of
inter-related factors. The first, as illustrated, is the lack of
high-quality studies providing evidence-based answers to
the various specific questions pertaining to the treatment of
MOH, which is essentially based on drug withdrawal.
MOH is not simply a highly frequent migraine or TTH and,
consequently, efforts to treat MOH by applying the basic
principles of primary headache therapy are often unsuc-
cessful. Second, the pathophysiological mechanisms
underlying MOH are poorly understood. Indeed, MOH is
an extremely heterogeneous disorder with regard to many
factors, such as type of primary headache, genetic predis-
position, pattern and severity, types of drug overused,
psychiatric and physical comorbidities, socio-environ-
mental pressures on individual patients and individual
patients’ past therapeutic experiences. As a result, there
probably exists no single therapeutic strategy that is
effective in every patient. Future studies should consider
the heterogeneity of MOH, to promote the development of
therapeutic strategies that can be tailored to the clinical
peculiarities of every single patient. Finally, MOH is
underestimated and, in some way, encouraged by those
physicians who instruct patients with a high frequency of
attacks to take the symptomatic drug as early as possible,
thereby reinforcing a drug-centred pain-coping strategy
that is very difficult to reverse.
Currently, the only reasonable strategy is to prevent the
development of MOH by educating patients and providing
them with adequate and accurate general information,
drawing their attention to the information given in the
instructions leaflets contained in the packages of all
potential risk drugs and monitoring them closely. More
specifically, targeted education and information pro-
grammes could effectively increase awareness of this lar-
gely underestimated clinical entity. Patients seeking
treatment should be informed of the risks of overusing
symptomatic headache drugs, the consumption of which
should be restricted to a maximum prescribed monthly
dosage. As a general rule, a preventive medication should
be started when a patient regularly requires acute treatment
on more than 2 days a week. Early initiation of headache
prophylaxis, either a medical or a behavioural approach, is
a powerful means of avoiding MOH. Headache drugs
containing barbiturates, caffeine, codeine or sedatives, as
well as mixed analgesics, are the worst offenders and
should be avoided. The main problem is that these com-
pounds are available as over-the-counter drugs and those
who use them may not seek professional and more ade-
quate treatment. International and national institutions
should step up their efforts to spread the message that
frequent use of acute attack medication constitutes misuse.
Future longitudinal population-based studies will help us to
identify the patients who are at risk of developing MOH
and to adjust preventive strategies accordingly.
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